

Challenges in multidisciplinary medical rehabilitation - Swyer-James-MacLeod Syndrome: case presentation and short literature review

ANTON Adelina¹, GHERGHISAN Ioana Sinziana², OMER (Gheorghe) Angela¹,
IONESCU Elena Valentina^{3,4}, ILIESCU Madalina Gabriela^{3,4}, BAZ Radu⁵

Corresponding author: Ioana Sinziana Gherghisan, E-mail: ioana.husaru@gmail.com

¹Department of Pulmonology and Internal Medicine, County Clinical Hospital of Constanta, Romania

²Department of Pulmonology, Clinical Pulmonology Hospital of Constanta, Romania

³Department of Medical Rehabilitation, Faculty of Medicine, Ovidius University of Constanta, Romania

⁴Romania Balneal and Rehabilitation Sanatorium of Techirghiol, Romania

⁵Department of Radiology, Faculty of Medicine, Ovidius University of Constanta, Romania

Abstract

Introduction. Swyer-James-MacLeod syndrome (SJMS) or unilateral hyperlucent lung syndrome is a rare disorder caused by infectious bronchiolitis obliterans and pneumonitis occurring in childhood. It is characterized by hypoplasia and/or agenesis of the pulmonary arteries resulting in pulmonary parenchyma hypoperfusion. **Materials and methods.** We report the case of a 27 years-old female patient who presented with progressive dyspnea, productive cough, fever and chills. **Results and discussion.** Chest radiography showed unilateral loss of left lung volume with hyperlucency. Unilateral reduction in vascularity with reduced caliber of the left pulmonary artery was revealed on CT scan of the chest, final diagnosis of SJMS being confirmed by angiography. **Conclusions.** This case strongly supports the recommendation of considering SJMS within the differential diagnosis workup of bronchiectasis, the syndrome being usually underdiagnosed.

Key words: *pulmonary, rehabilitation, multidisciplinary,*

Introduction

Swyer-James-MacLeod syndrome is a rare entity characterized by hypoplasia and/or agenesis of the pulmonary arteries resulting in pulmonary parenchyma hypoperfusion. It is considered an acquired disease secondary to viral bronchiolitis and pneumonitis during childhood and is etiologically associated with viruses, atypical germs or Mycobacterium tuberculosis (1-4). Its incidence was 0.01% in an X-ray study conducted on 17450 patients (5,6). SJMS was firstly described in 1953 by Swyer and James, by documenting the case of a child with unilateral hypertransparent lung without atelectasis (7). One year later, MacLeod published nine similar cases (8). The aim of the paper is to describe the clinical and paraclinical features of one patient with Swyer-James-MacLeod syndrome and to do a short literature review on the topic.

Material and methods

A twenty-seven year old female patient, Caucasian, nonsmoker, presented to the Emergency Department of our hospital for a ten-day history of progressive dyspnea, productive cough, fever (39°C) and chills. Empiric antibiotic therapy was prescribed with

progressive worsening of her symptoms. For a comprehensive examination, the patient was hospitalized in the Internal Medicine Department, stating no significant family medical history. She disclosed recurrent episodes of pulmonary infections during childhood and adolescence, which were treated with antibiotics and bronchodilators.

Results

The physical examination was unremarkable, except lung auscultation, which revealed crackles on the left side. The complete blood count showed leukocytosis (14720 cells/ μ l). The patient tested negative for alpha1-antitrypsin deficiency and sweat chloride test, whereas serum immunoglobulins levels were within normal limits. Sputum cultures were positive for Citrobacter spp. Pulmonary function tests suggested relevant irreversible moderate obstructive disease: post-bronchodilator values of forced expiratory volume in one second (FEV₁) forced vital capacity (FVC) and FEV₁/FVC ratio were: 44%, 63% and 60% respectively. The chest radiography showed small left lung and apical lucency area in the left lung. Thoracic computed

tomography (CT) scans revealed a small, hyperlucent left lung with cystic bronchiectasis, compensatory hyperinflation of the right lung and reduced caliber of the left pulmonary artery (figure 1). The CT angiography confirmed diffuse hypoplasia of the left pulmonary artery (figure 2). Patient management included bronchodilators, targeted antibiotics and expectorants. Seven days later, due to symptomatic improvement under current treatment, the patient was discharged with recommendations of regular follow-ups and influenza and pneumococcal vaccinations.

Discussions

Swyer-James-MacLeod syndrome is a rare lung disease, also known as “unilateral translucent lung” or “unilateral emphysema”. The hallmark of the syndrome is pulmonary arteries’ hypoplasia and/or agenesis, resulting in pulmonary parenchyma hypoperfusion, with characteristic radiological pattern - translucent or hyperlucent unilateral lung (6).

SJMS is an acquired illness secondary to childhood infectious bronchiolitis and pneumonitis, which are important clues, when found during anamnesis. Possible etiology may include viruses (Paramyxovirus, Morbillivirus, Influenza A, Adenovirus types 3, 7 and 21), atypical germs (*Bordetella pertussis*, *Mycoplasma pneumoniae*) and *Mycobacterium tuberculosis* (MTB) (5, 9). Infection with MTB is still very common in our country, overlapping with other rare conditions (10) and resulting in tuberculosis active disease in immunosuppressive conditions (11-14). Repeated infection causes an inflammatory reaction with consecutive obliteration of the peripheral airways and of the vessels, affecting the development of the organ. The affected lung becomes smaller than the healthy one, destruction of the alveolar walls leading to bronchiectasis and emphysema (5, 9). Unlike the majority of respiratory diseases, in which tobacco use or environmental exposures represent the most important risk factors (15-19), SJMS is not usually associated with smoking. Only the clinical assessment of smokers is not enough, but adding a biological evaluation will give the great picture of the problem (20).

Patients with SJMS are either asymptomatic, or, more frequently, they present non-specific respiratory symptoms (hemoptysis, dyspnea, chest pain, chronic cough, wheezing) which are commonly present in many other respiratory conditions (18). SJMS may also associate recurrent respiratory infections. Physical examination is

nonspecific: decreased chest expansion, wheezing, bronchial rales, crackles, hyper resonance (9, 21).

Respiratory function tests (RFTs) usually reveal a mild to moderate obstructive pattern: decreased FEV₁/FVC ratio, decreased FEV₁, bronchial hyperresponsiveness, decreased DLCO, severe air-trapping, increased RV/TLC ratio (residual volume/total lung capacity), and normal/slightly decreased lung volume. Frequently, these patients are misdiagnosed with chronic obstructive diseases such as asthma or chronic obstructive pulmonary disease (COPD) (21).

Diagnosis is mostly based on imaging studies. Radiographic changes may appear in a few months to a few years after the etiological infection and include: unilateral, unique hypertransparent lung, decreased pulmonary markings, small hilum, and mediastinum shift to the affected side. Furthermore, the involved lung fails in growing and exhibits minimal volume changes during breathing (9). CT-scans are mandatory for a complete positive diagnosis, revealing characteristic findings in the involved lung: small size, decreased lung attenuation, hyperlucency, bronchiectasis (in 30% of patients) and a mosaic pattern of air trapping (9, 21). The presence of bronchiectasis reveals severe exacerbations with poorer prognosis. Characteristic changes can also be found during nuclear medicine imaging procedures, such as decreased perfusion and decreased gas exchange during ventilation in the affected lung as compared to the healthy one (6, 9). Angiography is a helpful tool, showing small and/or hypoplastic pulmonary artery and branches in the involved lung (9).

Bronchoscopy is mainly recommended for differential diagnosis purposes, the endoscopic appearance being similar to chronic bronchitis. Bronchoalveolar lavage (BAL) shows inflammatory alveolitis, with increased cellularity (increased number of neutrophils) sometimes lymphocytes), increased number of CD8⁺ lymphocytes and decreased CD4⁺/CD8⁺ ratio. The considerable presence of B-cells (CD19⁺ cells) in the BAL fluid collected from our patient is an interesting finding, the given subpopulation having a normal concentration when examined by flow cytometry in the peripheral blood. This aspect suggests a hyperimmune reaction occurring in the lung, which might play a role in the subsequent development of the pulmonary impairment following the initial lung infection. A significant increase in the polyclonal B-cell lymphocytes’ number can be related to

bronchus-associated lymphoid tissue hyperplasia. Cases of follicular bronchiolitis sustained by latent adenoviral infection have been reported, suggesting that the lungs of these patients respond to persistent (unknown) antigenic stimulation by activating local immunological mechanisms (22).

A positive diagnosis requires positive history of respiratory infection and one of the following imaging requests: unilateral loss of lung volume with associated hyperlucency (chest X-ray), unilateral reduction in vascular density (chest CT) and unilateral diminished arterial perfusion (Tc 99m lung scan) (23).

Differential diagnosis needs exclusion of pulmonary thromboembolism, asthma, and COPD, lung imaging, PFTs, and absence of therapeutic response being important helpful tools. A hyperlucent lung is an alarming radiographic finding, case in which congenital lobar emphysema, bullous emphysema, pneumothorax, bronchiectasis with air trapping, bronchial stenosis and obliterative bronchiolitis must all be taken into consideration. It is also mandatory to exclude other vascular pathologies, such as congenital pulmonary agenesis or hypoplasia and acquired stenosis or compression of the main pulmonary vessels. None of these abnormalities would both produce diffuse, peripheral ventilatory defects on the single breath image and unilateral lung hypoplasia. Furthermore, air trapping and perfusion modifications are both missing in primary arterial defect and pulmonary thromboembolism (9). The course of the disease includes recurrent pulmonary infections, bronchiectasis and eventually, respiratory failure (24-27). The prognosis is worse in the presence of bronchiectasis (21, 22).

Treatment of SJMS is usually conservative and consists in preventive respiratory infection therapy and/or curative treatment with antibiotics, bronchodilators associated or not with low-dose inhaled corticoids and pulmonary rehabilitation with complex methods, using even natural therapeutic factors (28-31). In selected cases, such as chronic infection with lung parenchyma destruction, surgical treatment might be useful, including pulmonary lobectomy or pneumectomy (21), multidisciplinary rehabilitation programs after surgery being also necessary (32, 33). Before drastic measures are initiated, multimodal should be assessed to guide both short- and long-term treatment options, including pulmonary rehabilitation, trying to find a marker for monitoring the effect of the therapeutic measures for

these patients including radiological parameters (34, 35, 36).

Conclusions

We hereby report the case of a patient with positive medical history and characteristic radiological findings. Although he described recurrent respiratory infections during childhood and adolescence each time when admitted to the hospital, the indolent course of the disease and the non-characteristic chest scans led to late diagnosis. We strongly recommend considering SJMS within the differential diagnosis workup of bronchiectasis, the syndrome being underdiagnosed when having in mind the epidemiological data.




Fig. 1. Thoracic CT scan: small hyperlucent left lung with diminished vascularity and large cystic bronchiectasis, compensatory hyperinflated right lung



Fig. 2. CT angiography reconstruction: reduced caliber of the left pulmonary artery

Author contributions.

The authors contributed equally to the work.

Declaration of conflict of interests. There is no conflict of interest for any of the authors regarding this paper.

Informed consent. An informed consent was obtained from the patient included in this study.

References

1. Capela C, Gouveia P, Sousa M, Regadas MJ. Adult diagnosis of Swyer-James-MacLeod syndrome: a case report. *J Med Case Rep.* 2011; 5:2.
2. Tortajada M, Gracia M, García E, Hernández R. Diagnostic considerations in unilateral hyperlucency of the lung (Swyer-James-MacLeod Syndrome). *Allergol Immunopathol (Madr)* 2004, 32:265-270.
3. Fregonese L, Girosi D, Battistini E, Fregonese B, Risso FM, Bava GL, Rossi GA: Clinical, physiologic, and roentgenographic changes after pneumonectomy in a boy with Macleod/Swyer-James syndrome and bronchiectasis. *Pediatr Pulmonol* 2002, 34(5):412-416.
4. Sen HS, Taylan M, Abakay O, Sezgi C, Cetincakmak MG. Adult diagnosis of Swyer-

- James-Macleod syndrome: retrospective analysis of four cases. *Respir Care.* 2014 Apr. 59 (4):e51-4.
5. Dirweesh A, Alvarez C, Khan M, Shah N. A unilateral hyperlucent lung - Swyer-James syndrome: A case report and literature review. *Respir Med Case Rep.* 2017; 20:104–106.
6. Gaensler EA. Unilateral hyperlucent lung. In: Simon M, Potcher EJ, LeMay M (eds.): *Frontiers of Pulmonary Radiology.* New York, Grune & Stratton, 1969; 312-359.
7. Swyer PR, James GCW. A case of a unilateral pulmonary emphysema. *Thorax.* 1953; 8:133-136.
8. Macleod WM. Abnormal transradiancy of one lung. *Thorax.* 1954; 9,147-153.
9. Beverly PW et al., Swyer –James Syndrome Imaging, available at <https://emedicine.medscape.com/article/361906>
10. Fildan AP, Toma CL, Tofolean D, Balteanu M, Dantes E. Overlapping tuberculosis in a patient with pulmonary alveolar proteinosis. *Acta Medica Mediterranea,* 2016, 32:1021-1025.
11. Dantes E, Tofolean D, Fildan A.P, Craciun L, Dumea E, Tofolean IT, Mazilu L. Lethal disseminated tuberculosis in patients under biological treatment – two clinical cases and a short review. *J Int Med Res.* 2018;46(7):2961-2969.
12. Fildan AP, Toma CL, Tofolean D, Arghir OC, Dantes E. TB Risk in Patients with Biological Therapy for Psoriasis. *Chest.* 2016;150(4_S):201A.
13. Man MA, Nitu MF, Strambu L et al. Tuberculous constrictive pericarditis complicated with tuberculous mediastinitis-case report. *Romanian Journal of Morphology & Embryology* 2016;57(1):237-242.
14. Man MA, Arghir OC, Man S et al. Fatal paradoxical cryptic military tuberculosis and immune reconstitution disease in a young non-HIV immunocompromised male patient: case report with autopsy findings. *Romanian Journal of Morphology & Embryology* 2014;55(2):453-457.
15. Tudorache E, Fildan AP, Frandes M, Dantes E, Tofolean D. Aging and extrapulmonary effects of chronic obstructive pulmonary disease. *Clin Interv Aging.* 2017; 12:1281-1287.
16. Dantes E, Lilius G, Fildan AP. Environmental smoke exposure – an independent risk factor for

- lung cancer? *J Environ Prot Ecol*, 2015;16(4):1620-1626.
17. Toma CL, Dantes E, Oancea C, Fildan AP. Respiratory bronchiolitis - associated interstitial lung disease - an unexpected form of idiopathic interstitial pneumonia in a young male. *Rom J Morphol Embryol* 2017, 58(1):261–265.
 18. Dantes E, Fildan AP, Toma CL, Voicu GH, Oancea C. Respiratory impact in workers exposed to air pollutants from petroleum refinery. *J Environ Prot Ecol*. 2016; 17(2): 523-531.
 19. Trofor AC, Man MA, Marginean C, Dumitru F, Trofor L. Smoking cessation for free: outcomes of a study of three Romanian clinics. *Open Medicine*. 2016; 11(1): 605-610.
 20. Trofor A, Petris O, Trofor L et al. Biochemistry in Assessing Tobacco Exposure-Smokers versus Non-smokers. *Rev.Chim.(Bucharest)* 2017; 68(5) 1002-1006.
 21. Machado D, Lima F, Marques C, Monteiro R. Swyer-James-Macleod syndrome as a rare cause of unilateral hyperlucent lung: Three case reports. *Medicine (Baltimore)*. 2019;98(6):e14269.
 22. Bernardi F, Cazzato S, Poletti V, Tassinari D, Burnaccini M, Zompatori M, Cacciari E. Swyer-James syndrome: bronchoalveolar lavage findings in two patients. *Eur Respir J*, 1995;8(4):654-7.
 23. Chaucer B, Chevenon M, Toro C, Lemma T, Grageda M. Swyer-James-Macleod syndrome; a rare finding and important differential in the emergency room setting. *American Journal of Emergency Medicine*. 2016; 34:1329.e3–1329.e4
 24. Arghir OC, Dantes E, Otelea MR, Rascu A, Borgazi E, Cambrea SC. Eight year survey of tuberculosis in-hospital mortality in the South Eastern part of Romania. *Rom Journal of Legal Medicine*, 2018, 26 (2), 183.
 25. Arghir OC, Pereira PMA, Rascu A, Dantes E, Borgazi E, Iliescu DM, Otelea MR, Cambrea SC. The impact of Migrant Tuberculosis on the Chimioresistance pattern of antituberculosis drugs in a low burden tuberculosis European Country. *Farmacia*, 2018, 66 (3), 537.
 26. Cambrea SC, Petcu LC, Mihai CM, Hangan TL, Iliescu DM. Influence of environmental factors about evolution of Shigellosis in Constanta county of Romania. *J Environ Prot Ecol*.. 2019, 20, No 2, 986–994.
 27. Halichidis S, Balasa AL, Ionescu EV, Iliescu MG, Cambrea SC, Petcu LC, Mihai CM. Evolution of Salmonellosis in Constanta area in correlation with environmental factors. *J Environ Prot Ecol*.. 2019, 20, No 3, 1496–1504.
 28. Lupu AA, Ionescu EV, Iliescu MG, Almasan RE, Oprea C, Ion I, Iliescu DM. Effect of Techirghiol specific climate factors on the patients quality of life with degenerative lumbar pain. *J Environ Prot Ecol*. 2018, 19 (4), 1857.
 29. Berbece S, Iliescu D, Ardeleanu V, Nicolau A, Jecan RC. Use of Phosphatidylcholine in the Treatment of localized fat deposit results and expectation. *Rev.Chim.(Bucharest)* 2017, 68 (7),1438.
 30. Iliescu MG, Profir D, Surdu O, Marin V, Demirgean S, Almasan RE, Stanciu LE, Oprea C, Iliescu DM, Ionescu EV. Statistical View Through Balneal Activity In Techirghiol Medical Area. *J Environ Prot Ecol*. 2018, 19(1), 382.
 31. Almasan RE, Ionescu EV, Iliescu MG, Oprea C, Iliescu DM, Nenciu MI, Golumbeanu M. Techirghiol lake in the context of the integrated development of health tourism. *J Environ Prot Ecol*. 2019, 20, No 1, 206–213.
 32. Oprea C, Ionescu EV, Iliescu MG, Almasan RE, Calota N, Iliescu DM. Monitoring and evaluation of patients satisfaction in medical units that use natural factors for treatment. *J Environ Prot Ecol*. 2019, 20, No 1, 447-452.
 33. Tucmeanu AI, Popescu DM, Ionescu EV, Almasan RE, Oprea C, Mociu A, Iliescu MG, Iliescu DM. Management Consultancy for Organisational Change in Health from the Manager Perspective. *J Environ Prot Ecol*. 2017, 18 (3), 1238.
 34. Tica I, Lupu A, Botnarcuic M, Petcu L, Oprea C, Badiu RG, Iliescu DM, Ionescu EV, Tica VI; Iliescu MG. Brain - Derived Neurotrophic Factor - a Marker for the Balneal Treatment of Chronic Low Back Pain? *Rev.Chim.(Bucharest)* 2019, 70,9, 3180.
 35. Iliescu DM, Bordei P, Ionescu EV, Albina S, Oprea C, Obada B, Lupu AA, Hangan TL, Iliescu MG. Anatomic-imaging correlations of lumbar disk-vertebral morphometric indices. *Int. J. Morphol*. 2017, 35(4):1553-1559.
 36. Calota N. - Techniques and methods used in neurological rehabilitation. Ovidius University Press. 2016, 126-128, ISBN 978973-614-936-8.